UK markets open in 6 hours 10 minutes

Nexstim Plc (NXTMH.HE)

Helsinki - Helsinki Real-time price. Currency in EUR
Add to watchlist
4.6500+0.1400 (+3.10%)
At close: 5:03PM EEST
Full screen
Previous close4.5100
Open4.6300
Bid4.6600 x N/A
Ask4.6900 x N/A
Day's range4.6100 - 4.7700
52-week range3.4100 - 9.6302
Volume11,883
Avg. volume25,670
Market cap31.093M
Beta (5Y monthly)2.25
PE ratio (TTM)N/A
EPS (TTM)-0.7910
Earnings date13 Aug 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Nexstim Receives an NBS System Order from a Hospital in the Middle East

    Press release, Helsinki, 27 October 2021 at 9 AM (EEST) Nexstim Receives an NBS System Order from a Hospital in the Middle East Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces having received an NBS system order from a hospital in the Middle East. Nexstim’s NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain. This specific NBS system also includes the software of an NBT® system, allowin

  • Globe Newswire

    Nexstim Releases the New NBS5+ in the United States

    Press release, Helsinki, 22 October 2021 at 9 AM (EEST) Nexstim Releases the New NBS5+ in the United States Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the launch of a new navigated transcranial magnetic stimulation (nTMS) system configuration in the United States, to further strengthen competitive advantage in this market. The US will now have access to a new NBS (Navigated Brain Stimulation) System 5 configuration, NBS5+. The new configuration adds the NBT® (Navigated

  • Globe Newswire

    Nexstim Plc Business and Clinical Update Q3 2021

    Press release, Helsinki, 20 October 2021 at 10:00 AM (EEST) Nexstim Plc Business and Clinical Update Q3 2021 Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces the key highlights of the Company’s business and clinical progress during Q3 2021. CEO Mikko Karvinen’s Business and Clinical Update I’m very happy to inform that following the strongest first half in the history of the company, our operational business has continued to show positive progress during the third quarter of